MedPlus Health Services Limited has informed stock exchanges about multiple regulatory actions affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, has received suspension orders for drug licenses across multiple stores in different states.

Latest Regulatory Actions

The company has received two additional suspension orders following the earlier action in Telangana. The latest orders affect stores in Andhra Pradesh and Odisha, with varying suspension periods and financial impacts.

Cumulative Financial Impact

The combined effect of all three suspension orders represents a significant operational disruption for the subsidiary. The total potential revenue loss across all affected stores amounts to Rs 6.81 lacs, with the Andhra Pradesh store suspension contributing the largest impact due to its seven-day duration.

Regulatory Compliance Framework

All violations fall under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The disclosures are being made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in compliance with SEBI circulars dated July 13, 2023, and December 31, 2024.

Corporate Communication

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on BSE and NSE websites. The latest disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on April 15, 2026.

Medplus health services Limited has completed its regulatory filing requirements by submitting the mandatory compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The pharmaceutical retail chain fulfilled its quarterly compliance obligations through proper documentation and filing procedures.

Regulatory Compliance Filing

The company filed the required certificate with stock exchanges on April 06, 2026, through Company Secretary and Compliance Officer Manoj Kumar Srivastava. The filing ensures adherence to SEBI (Depositories and Participants) Regulations, 2018, specifically under Regulation 74(5) requirements.

Stock Exchange Submissions

MedPlus Health Services submitted the compliance documentation to both major Indian stock exchanges where its shares are listed. The certificates were addressed to the listing departments of BSE Limited and National Stock Exchange of India Limited, ensuring comprehensive regulatory coverage.

Registrar Certification Process

KFIN Technologies Limited, serving as the company's Registrar and Transfer Agent, issued the compliance certificates on April 01, 2026. Deputy Vice President Bhaskar Roy signed the certificates confirming that securities dematerialization and rematerialization details were properly furnished to stock exchanges during the specified quarter.

Depository Compliance

The registrar submitted identical certificates to both major depositories in India - National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). These submissions ensure complete compliance across the entire securities infrastructure ecosystem.

Document Availability

The compliance certificates are accessible through multiple channels for stakeholder reference. The company has made the documentation available on its official website at www.medplusindia.com , along with the websites of BSE Limited and National Stock Exchange of India Limited for transparent access to regulatory filings.